Compare Hasbro, Inc. (HAS) vs Summit Therapeutics Inc (SMMT) Price & Performance

Hasbro (HAS) trades at $94.22, up 3.82% today, showing strong momentum after recent earnings beats. The stock maintains a bullish technical stance with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, the company demonstrates robust profitability with 64.41% gross margins and impressive ROE of 167.83%, despite a net loss in 2025. Analyst consensus remains positive with 51.52% buy ratings and a $107.60 price target, representing 14% upside potential from current levels.

Investment outlook appears favorable with strong gaming segment growth and cost-saving initiatives driving projected 2026 net income of $794 million. Key risks include high debt levels at 59.09% debt-to-asset ratio and competitive pressures in the toy industry. The upcoming Q3 2026 earnings report on October 20 will be crucial for validating the company's turnaround trajectory and growth projections.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.